Login to Your Account



Array's binimetinib improves PFS for patients with NRAS-mutant melanoma

By Michael Fitzhugh
Staff Writer

Wednesday, December 16, 2015

Shares of Array Biopharma Inc. (NASDAQ:ARRY) climbed 20.6 percent to $4.62 on Wednesday following news that its MEK inhibitor, binimetinib, improved progression-free survival (PFS) for patients with advanced NRAS-mutant melanoma compared to chemotherapy during the phase III Nemo study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription